Wells Fargo Maintains Overweight on Ventyx Biosciences, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Overweight rating on Ventyx Biosciences (NASDAQ:VTYX) but lowers the price target from $16 to $11.
August 12, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo maintains an Overweight rating on Ventyx Biosciences but lowers the price target from $16 to $11.
The lowered price target from $16 to $11 suggests a less optimistic outlook for Ventyx Biosciences, which could negatively impact the stock price in the short term despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100